TipRanks
Go Ultimate55% OFF

Michael Schmertzler Insider Profile

11 Followers

Michael Schmertzler, Director at PTC Therapeutics, holds 1.45M shares in PTC Therapeutics (Ticker: PTCT), holds 600.00K shares in Hamilton Lane (Ticker: HLNE), holds 4.34M shares in Cytokinetics (Ticker: CYTK).

Michael Schmertzler's Trading History

PTCT
PTC Therapeutics
Oct 16, 2026DirectorUninformative Sell149.04K$87.25M
HLNE
Hamilton Lane
Sep 08, 2025Ten Percent OwnerUninformative Sell―$50.35M
CYTK
Cytokinetics
Jun 07, 2010See Exhibit 1Informative Sell16.15K$273.43M

You May Also Like

Michael Schmertzler insider profile FAQ

What is the percentage of profitable transactions made by Michael Schmertzler?
The percentage of profitable transactions made by Michael Schmertzler is 100%.
What is the average return per transaction made by Michael Schmertzler?
The average return per transaction made by Michael Schmertzler is 49.30%.
What stocks does Michael Schmertzler hold?
Michael Schmertzler holds: PTCT, HLNE, CYTK stocks.
What was Michael Schmertzler’s latest transaction?
Michael Schmertzler’s latest transaction was an Uninformative Sell of $149.04K.
What was Michael Schmertzler's most profitable transaction?
Michael Schmertzler’s most profitable transaction was an Informative Buy of PTCT stock on January 29, 2019. The return on the trade was 81.70%.
What is Michael Schmertzler's role in PTC Therapeutics?
Michael Schmertzler's role in PTC Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.